Neuronetics (NASDAQ:STIM) EVP Steven Pfanstiel Sells 16,431 Shares

Neuronetics, Inc. (NASDAQ:STIM) EVP Steven Pfanstiel sold 16,431 shares of the company’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $1.34, for a total transaction of $22,017.54. Following the completion of the transaction, the executive vice president owned 828,781 shares in the company, valued at approximately $1,110,566.54. This represents a 1.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Neuronetics Stock Down 9.1%

Neuronetics stock opened at $1.46 on Wednesday. Neuronetics, Inc. has a fifty-two week low of $0.80 and a fifty-two week high of $4.97. The company has a debt-to-equity ratio of 2.51, a quick ratio of 1.87 and a current ratio of 2.02. The firm has a 50 day moving average price of $1.58 and a 200 day moving average price of $1.98. The company has a market capitalization of $100.80 million, a PE ratio of -2.47 and a beta of 0.87.

Neuronetics (NASDAQ:STIM) last announced its quarterly earnings data on Tuesday, March 17th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02. The business had revenue of $41.78 million for the quarter, compared to analysts’ expectations of $40.84 million. Neuronetics had a negative return on equity of 121.26% and a negative net margin of 26.15%. Research analysts expect that Neuronetics, Inc. will post -1.13 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on STIM shares. Wall Street Zen lowered shares of Neuronetics from a “hold” rating to a “sell” rating in a research note on Saturday. Canaccord Genuity Group dropped their price objective on Neuronetics from $7.00 to $3.00 and set a “buy” rating on the stock in a report on Thursday, March 19th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Neuronetics in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Neuronetics presently has an average rating of “Hold” and an average target price of $3.00.

Key Neuronetics News

Here are the key news stories impacting Neuronetics this week:

• Positive Sentiment: Company reported higher revenue, narrowed loss and set a 2026 outlook — this operational improvement and guidance can support valuation uplift. Neuronetics reports higher revenue, narrows loss, sets 2026 outlook
• Positive Sentiment: Major shareholder Jorey Chernett has been buying heavily (recent purchases total hundreds of thousands of shares across several days), signaling insider conviction and providing buying support. Neuronetics (NASDAQ:STIM) Major Shareholder Jorey Chernett Buys 169,472 Shares
• Neutral Sentiment: Board/management change — Dan Reuvers was appointed CEO, succeeding Keith Sullivan. Leadership changes introduce execution risk but may be neutral if transition is smooth. Neuronetics appoints Dan Reuvers as CEO, succeeding Keith Sullivan
• Neutral Sentiment: Analyses remain mixed — a Seeking Alpha piece calls STIM highly speculative but highlights revenue growth as a potential catalyst; this keeps sentiment bifurcated. Neuronetics: Highly Speculative, But Revenue Growth Could Drive The Stock Higher
• Neutral Sentiment: Short‑interest data released appears to contain errors (zero/NaN values), so no clear short‑pressure signal from official releases at this time.
• Negative Sentiment: Insider selling by executives and a director: EVP William Andrew Macan, EVP Steven Pfanstiel and Director Keith J. Sullivan sold shares on March 19th — such sales can be viewed negatively by the market even though insiders still retain large positions. SEC insider sale filings
• Negative Sentiment: Analyst moves and price‑target cuts: Canaccord trimmed its PT from $7 to $3 (still a buy), while other firms lowered ratings or maintained sell views — downward revisions and mixed analyst sentiment are pressuring the stock. MarketBeat STIM coverage (analyst updates)

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. HighTower Advisors LLC lifted its position in Neuronetics by 260.7% during the third quarter. HighTower Advisors LLC now owns 577,069 shares of the company’s stock worth $1,575,000 after buying an additional 417,087 shares during the period. UBS Group AG lifted its position in Neuronetics by 20.4% during the fourth quarter. UBS Group AG now owns 2,607,047 shares of the company’s stock valued at $3,598,000 after buying an additional 442,216 shares in the last quarter. Presidio Capital Management LLC boosted its position in Neuronetics by 217.0% during the 4th quarter. Presidio Capital Management LLC now owns 37,436 shares of the company’s stock worth $52,000 after purchasing an additional 25,625 shares during the period. David J Yvars Group boosted its position in shares of Neuronetics by 22.1% in the fourth quarter. David J Yvars Group now owns 31,230 shares of the company’s stock worth $43,000 after buying an additional 5,650 shares during the period. Finally, Centiva Capital LP boosted its holdings in Neuronetics by 110.2% in the 3rd quarter. Centiva Capital LP now owns 117,322 shares of the company’s stock worth $320,000 after acquiring an additional 61,501 shares during the period. 53.59% of the stock is currently owned by hedge funds and other institutional investors.

Neuronetics Company Profile

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.